Brian V Balgobind, MD1*, Sanne Lugthart, MD2*, Iris H.I.M. Hollink, MD1*, Susan T.J.C.M. Arentsen-Peters1*, Elisabeth R van Wering3, Sibold S.N. de Graaf, MD, PhD3*, Dirk Reinhardt, MD, PhD4, Gertjan Kaspers, MD, PhD5, Jan Stary, MD, PhD6*, Jan Trka, MD, PhD7*, Martin Zimmermann, PhD8*, Ruud Delwel, PhD2, Rob Pieters, Prof.1*, Christian M Zwaan, MD, PhD9 and Marry M van den Heuvel-Eibrink, MD, PhD1*
1Department of Pediatric Hematology/Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
2Erasmus University Medical Center, Rotterdam, Netherlands
3Dutch Childhood Oncology Group (DCOG), The Hague, Netherlands
4Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany
5VU University Medical Center, Amsterdam, Netherlands
6Dept of Pediatric Hematology and Oncology, 2nd Medical School, Charles University, University Hospital Motol, Prague, Czech Republic
7Pediatric Hematology/Oncology, Charles University, University Hospital Motol, Prague, Czech Republic
8Pediatric Hem./Onc., Medical School of Hannover, Hannover, Germany
9Department of Pediatric Hematology/Oncology, ErasmusMC Rotterdam-Sophia Children's Hospital, Rotterdam, Netherlands